Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Autologous TAPA-pulsed dendritic cell vaccine + Cyclophosphamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Autologous TAPA-pulsed dendritic cell vaccine||Autologous TAPA-pulsed dendritic cell vaccine is a vaccine comprised of autologous dendritic cells that have been pulsed with tumor-associated peptide antigens, which may initiate an immune response against tumor cells expressing the specific tumor associated peptide antigens (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02224599||Phase Ib/II||Autologous TAPA-pulsed dendritic cell vaccine + Cyclophosphamide||Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies||Terminated|